According to the phase III trial TROPiCS-02 findings, patients with HR-positive/HER2-negative metastatic BC who have undergone at least two prior lines of chemotherapy should be treated with sacituzumab govitecan (SG) [27]. This evidence concerns the gene ERBB2 and breast cancer.